| Recruiting | Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host NCT07249346 | Hannah Choe, MD | Phase 2 |
| Not Yet Recruiting | Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Synd NCT07468916 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Recruiting | Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloprolife NCT07071155 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | EARLY_Phase 1 |
| Recruiting | Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and NCT07046078 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations NCT06630221 | Abhay Singh, MD MPH | Phase 2 |
| Not Yet Recruiting | Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients NCT06900088 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Vers NCT06815003 | City of Hope Medical Center | Phase 2 |
| Recruiting | A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) NCT06950034 | Solu Therapeutics, Inc | Phase 1 |
| Recruiting | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis NCT06680661 | Leland Metheny | Phase 2 |
| Recruiting | Oral-ATO for TP53-mutated Myeloid Malignancies NCT06778187 | The University of Hong Kong | Phase 2 |
| Recruiting | A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutat NCT06597734 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell T NCT06543381 | City of Hope Medical Center | Phase 1 |
| Recruiting | A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Signifi NCT06566742 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CM NCT06647862 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase 3 |
| Recruiting | Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of P NCT06439199 | Nantes University Hospital | — |
| Recruiting | Pacritinib in CMML NCT06159491 | Douglas Tremblay | Phase 1 / Phase 2 |
| Recruiting | Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Ne NCT06523556 | Uma Borate | Phase 1 / Phase 2 |
| Recruiting | Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial NCT06355583 | Imperial College London | Phase 2 |
| Recruiting | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition NCT06218628 | Fox Chase Cancer Center | Phase 1 |
| Recruiting | Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myel NCT06071624 | Huda Salman | Phase 1 |
| Recruiting | Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvem NCT06111612 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Active Not Recruiting | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantati NCT06001385 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Withdrawn | High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD NCT05895201 | Indiana University | Phase 1 / Phase 2 |
| Withdrawn | Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Ch NCT06085638 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodys NCT05600894 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan f NCT05807932 | Heinrich-Heine University, Duesseldorf | Phase 1 / Phase 2 |
| Unknown | Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML NCT05970822 | Biocity Biopharmaceutics Co., Ltd. | Phase 1 |
| Completed | LILRB4 STAR-T Cell Therapy for Monocytic Leukemia NCT05739409 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Unknown | A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MD NCT05641259 | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 1 |
| Withdrawn | Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine NCT05246384 | Rhizen Pharmaceuticals SA | Phase 1 / Phase 2 |
| Withdrawn | Calprotectin, a Biomarker of COVID-19 Severity (CALPRO) NCT04953312 | Assistance Publique - Hôpitaux de Paris | N/A |
| Recruiting | Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies NCT05488548 | Epigenetix, Inc. | Phase 1 |
| Recruiting | Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS NCT05636514 | Clinical Hub for Interventional Research (CHOIR) | Phase 1 |
| Active Not Recruiting | Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patien NCT05364762 | City of Hope Medical Center | Phase 2 |
| Terminated | AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia NCT05209152 | Amgen | Phase 1 |
| Active Not Recruiting | Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin NCT04802161 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML a NCT05456269 | Race Oncology Ltd | Phase 1 |
| Recruiting | Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002 NCT05233618 | Karen Ballen, MD | Phase 1 |
| Active Not Recruiting | A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard o NCT05428969 | Faron Pharmaceuticals Ltd | Phase 1 / Phase 2 |
| Recruiting | Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML NCT05184842 | Montefiore Medical Center | Phase 2 |
| Terminated | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies NCT05107856 | Prelude Therapeutics | Phase 1 |
| Active Not Recruiting | Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloprolifera NCT05038592 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies NCT04937166 | Kahr Medical | Phase 1 |
| Recruiting | Two Step Haplo With Radiation Conditioning NCT05031897 | Thomas Jefferson University | Phase 2 |
| Recruiting | Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS NCT04708054 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Active Not Recruiting | Inqovi Maintenance Therapy in Myeloid Neoplasms NCT04980404 | Massachusetts General Hospital | Phase 1 |
| Completed | A Study of E7820 in People With Bone Marrow (Myeloid) Cancers NCT05024994 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Withdrawn | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis Af NCT03602898 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without G NCT04842604 | Pfizer | Phase 3 |
| Active Not Recruiting | A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML NCT04730258 | Treadwell Therapeutics, Inc | Phase 1 / Phase 2 |
| Unknown | Methods of T Cell Depletion Trial (MoTD) NCT04888741 | University of Birmingham | Phase 2 |
| Active Not Recruiting | Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders NCT04761770 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hemat NCT04195633 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome NCT04655755 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | NTX-301 in MDS/AML NCT04167917 | University of Alabama at Birmingham | Phase 1 |
| Unknown | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS NCT04358393 | Ascentage Pharma Group Inc. | Phase 1 / Phase 2 |
| Completed | A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) NCT04609826 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | Study to Evaluate the Safety and Tolerability of EP0042 NCT04581512 | Ellipses Pharma | Phase 1 / Phase 2 |
| Completed | Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced M NCT04146038 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT NCT04522895 | Heinrich-Heine University, Duesseldorf | Phase 2 |
| Recruiting | A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patien NCT04239157 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Haplo Peripheral Blood Sct In GVHD Prevention NCT04473911 | Zachariah Michael DeFilipp | Phase 1 |
| Recruiting | Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferativ NCT04493138 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant NCT03964506 | Omar Aljitawi | EARLY_Phase 1 |
| Recruiting | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With NCT04256317 | Taiho Oncology, Inc. | Phase 2 / Phase 3 |
| Terminated | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome NCT04160052 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Enrolling By Invitation | A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) NCT04093570 | Taiho Oncology, Inc. | Phase 2 |
| Recruiting | Combining Active and Passive DNA Hypomethylation NCT03999723 | Kirsten Grønbæk | Phase 2 |
| Active Not Recruiting | Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion NCT03722407 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Active Not Recruiting | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT NCT03912064 | Dana-Farber Cancer Institute | Phase 1 |
| Recruiting | 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Ris NCT03670966 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43 NCT03850574 | Aptose Biosciences Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT03862157 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes NCT03746041 | University of Rochester | Phase 1 |
| Completed | Effect of Food on Blood Levels of ASTX727 NCT03813186 | Astex Pharmaceuticals, Inc. | Phase 1 |
| Active Not Recruiting | Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or NCT03672539 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoi NCT03734601 | Stanford University | Phase 2 |
| Active Not Recruiting | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Diso NCT03289910 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 G NCT03683433 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine NCT03588078 | Groupe Francophone des Myelodysplasies | Phase 1 / Phase 2 |
| Completed | IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic NCT03515512 | Massachusetts General Hospital | Phase 1 |
| Completed | Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 NCT03493646 | Kirby Institute | Phase 2 |
| Completed | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelo NCT03358719 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomo NCT03418038 | Mayo Clinic | Phase 2 |
| Recruiting | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After NCT03326921 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression and Myelodysplastic Syndrom NCT03363399 | University Hospital, Grenoble | — |
| Completed | Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML NCT03306264 | Astex Pharmaceuticals, Inc. | Phase 3 |
| Terminated | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed NCT03404193 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome NCT03383575 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Pa NCT03333486 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome NCT03047993 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Ascorbic Acid Levels in MDS, AML, and CMML Patients NCT03526666 | Van Andel Research Institute | — |
| Recruiting | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, A NCT03128034 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractor NCT03263637 | AstraZeneca | Phase 1 |
| Completed | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients W NCT03096782 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS NCT03066648 | Novartis Pharmaceuticals | Phase 1 |
| Withdrawn | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferati NCT02564536 | Washington University School of Medicine | Phase 1 |
| Completed | Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms NCT03072043 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Completed | WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or NCT02666950 | Mayo Clinic | Phase 2 |
| Terminated | Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic NCT03146871 | University of Southern California | Phase 2 |
| Completed | Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT NCT03018223 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT02960646 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomon NCT02935361 | University of Southern California | Phase 1 / Phase 2 |
| Completed | Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplasti NCT02684162 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Personalized NK Cell Therapy in CBT NCT02727803 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome NCT02553941 | Brian Jonas | Phase 1 |
| Completed | Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leu NCT02649764 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) NCT02268253 | Stemline Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malig NCT02556931 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients Wi NCT02566304 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients NCT02367456 | Pfizer | Phase 1 |
| Completed | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Di NCT02397720 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML) NCT03280888 | Centre Hospitalier Universitaire de Nice | — |
| Completed | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies NCT02129101 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Le NCT01885689 | City of Hope Medical Center | Phase 2 |
| Unknown | Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leuke NCT01894477 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant NCT01812252 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay NCT01872819 | University of Washington | N/A |
| Completed | Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decit NCT01928537 | Traws Pharma, Inc. | Phase 3 |
| Completed | Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine NCT01926587 | Traws Pharma, Inc. | Phase 1 / Phase 2 |
| Completed | DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or A NCT01834248 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms NCT01908387 | Celgene Corporation | Phase 1 |
| Completed | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignan NCT01823198 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hemato NCT01789255 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01664897 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodyspla NCT01831232 | Fred Hutchinson Cancer Center | N/A |
| Completed | Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS NCT02190695 | Fox Chase Cancer Center | Phase 2 |
| Terminated | GVAX vs. Placebo for MDS/AML After Allo HSCT NCT01773395 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies NCT01760655 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloi NCT01757639 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylax NCT01749111 | Hospital Israelita Albert Einstein | Phase 3 |
| Completed | Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) NCT01736683 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015 | City of Hope Medical Center | Phase 1 |
| Completed | Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia NCT01772420 | Albert Einstein College of Medicine | Phase 2 |
| Completed | Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia NCT01629082 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Terminated | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelog NCT01620216 | OHSU Knight Cancer Institute | Phase 2 |
| Withdrawn | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant NCT01558778 | Roswell Park Cancer Institute | N/A |
| Active Not Recruiting | Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic S NCT01522976 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With NCT01300572 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Trans NCT01427881 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies NCT01384513 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients NCT01398462 | JW Pharmaceutical | Phase 1 |
| Completed | 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patie NCT01404741 | Universitätsklinikum Hamburg-Eppendorf | Phase 2 |
| Completed | Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation NCT01338987 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia NCT01350947 | University of Utah | Phase 2 |
| Completed | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or NCT01305200 | Children's Oncology Group | Phase 3 |
| Completed | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia NCT01484015 | Wake Forest University Health Sciences | Phase 1 |
| Completed | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01231919 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Completed | Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts NCT01241500 | Traws Pharma, Inc. | Phase 3 |
| Completed | PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias NCT01169012 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Completed | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Tran NCT01233921 | Martin, Paul | N/A |
| Unknown | Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure NCT01133886 | King's College London | Phase 2 |
| Completed | Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Adva NCT01101880 | University of Washington | Phase 2 |
| Terminated | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload NCT01159067 | City of Hope Medical Center | Phase 2 |
| Completed | Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome NCT01165996 | Case Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | Veliparib and Temozolomide in Treating Patients With Acute Leukemia NCT01139970 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Lenalidomide in Patients With Chronic Myelomonocytic Leukemia NCT01368757 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Phase 1 / Phase 2 |
| Completed | Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High- NCT00988715 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or A NCT01083706 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494 | Wake Forest University Health Sciences | N/A |
| Completed | Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia NCT01251627 | Fondazione Italiana Sindromi Mielodisplastiche-ETS | Phase 2 |
| Completed | Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Ch NCT01048034 | Nordic MDS Group | Phase 2 |
| Completed | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult NCT00946647 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Terminated | The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia NCT01010256 | University of Arkansas | — |
| Completed | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia NCT01146210 | Children's Oncology Group | — |
| Completed | Registry on Hypomethylating Agents in Myeloid Neoplasms NCT01595295 | Arbeitsgemeinschaft medikamentoese Tumortherapie | — |
| Completed | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Pa NCT00860574 | Fred Hutchinson Cancer Center | Phase 2 |
| Unknown | A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediat NCT00885508 | Groupe Francophone des Myelodysplasies | Phase 2 |
| Active Not Recruiting | Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia NCT00843882 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With NCT00856388 | Roswell Park Cancer Institute | N/A |
| Completed | Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML) NCT01098084 | Groupe Francophone des Myelodysplasies | Phase 2 |
| Completed | Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leuke NCT00809250 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant NCT00795769 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors NCT00799461 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Phase 3 |
| Completed | A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies NCT00719836 | S*BIO | Phase 1 / Phase 2 |
| Terminated | Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic NCT00708721 | University of Utah | Phase 1 / Phase 2 |
| Completed | Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leu NCT00588991 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Dono NCT00589316 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01093586 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in NCT00852709 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Terminated | Aflibercept in Treating Patients With Myelodysplastic Syndromes NCT00509249 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myelo NCT00462605 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia NCT00451048 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia NCT00392353 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Sunitinib in Treating Patients With Idiopathic Myelofibrosis NCT00387426 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, NCT00381550 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonoc NCT00313586 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem NCT00408681 | Fred Hutchinson Cancer Center | N/A |
| Completed | Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer NCT00357708 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases NCT00351975 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or M NCT00357305 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Oral Clofarabine Study in Patients With Myelodysplastic Syndrome NCT00299156 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treati NCT00397813 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome NCT00283114 | Seagen Inc. | Phase 1 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofe NCT00118352 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure NCT00113321 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, o NCT00101179 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lym NCT00098423 | National Cancer Institute (NCI) | Phase 1 |
| Completed | XK469R in Treating Patients With Refractory Hematologic Cancer NCT00095797 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or NCT00096122 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes NCT00171912 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic S NCT00087204 | National Cancer Institute (NCI) | Phase 1 |
| Completed | CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, NCT00084916 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloge NCT00079313 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Terminated | Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CM NCT00074750 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) NCT00067808 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Trans NCT00119366 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leuke NCT00052520 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Tipifarnib in Treating Patients With Myelodysplastic Syndromes NCT00005845 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) NCT00136409 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Myelofibrosis NCT00039416 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Tr NCT00027820 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and NCT00038675 | M.D. Anderson Cancer Center | N/A |
| Completed | Thalidomide in Treating Patients With Myelodysplastic Syndrome NCT00015990 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer NCT00012376 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Imm NCT00014235 | Fred Hutchinson Cancer Center | N/A |
| Completed | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporin NCT00006251 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferent NCT02210858 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initi NCT00005942 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593 | Fred Hutchinson Cancer Center | N/A |
| Completed | Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed NCT00008177 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies NCT00038051 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogeno NCT00002798 | National Cancer Institute (NCI) | Phase 3 |